CN102462695B - Application of sodium sulfite - Google Patents
Application of sodium sulfite Download PDFInfo
- Publication number
- CN102462695B CN102462695B CN201110349992.5A CN201110349992A CN102462695B CN 102462695 B CN102462695 B CN 102462695B CN 201110349992 A CN201110349992 A CN 201110349992A CN 102462695 B CN102462695 B CN 102462695B
- Authority
- CN
- China
- Prior art keywords
- hypoxia
- ischemia
- sodium sulfite
- health product
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a novel application of sodium sulfite (Na2SO3), that is, an application in preparing medicines, health products, functional drinks or functional food for preventing hypoxia-induced injury and/or diseases related to ischemia-hypoxia. According to the invention, by using Na2SO3 as an active component in preparing medicines, health products, functional drinks or functional food for preventing hypoxia-induced injury and/or diseases related to ischemia-hypoxia, the body can be in a hypoxia (such as high altitude hypoxia, mine hypoxia, and the like ) preconditioning state, thus the purpose of preventing hypoxia-induced injury and/or diseases related to ischemia-hypoxia (such as high altitude pulmonary edema, high altitude cerebral edema, cerebral ischemia, cardiac ischemia, respiratory distress, and the like) can be achieved. The medicines disclosed herein have the following advantages: 1) obvious curative effect; 2) no toxic and side effect, and high safety; 3) low price of Na2SO3; and 4) convenience in drug use (convenience in carrying and taking).
Description
Technical field
The invention belongs to the new purposes of compound, particularly relate to the application of sodium sulfite in medicine and/or the health product of preparation prevention hypoxia injury and/or hypoxia-ischemia relevant disease.
Background technology
Oxygen is the basis of organism vital movement, and the factors such as the relative closure spaces such as plateau, mine and angiemphraxis and disturbance of blood circulation can cause hypoxia in various degree.Hypoxia not only can make life entity physiological function change, and can cause a series of damage and pathological changes when serious, as brain hypoxia-ischemia can cause apoplexy and nervous system degenerative disease, and the long-time hypoxia of the organs such as the heart, liver and kidney also can cause organ injury, meanwhile, Altitude also easily causes the diseases such as high altitude cerebral adema and plateau pneumochysis.
If the people who lives in plains region is without abundant adaptation; while rising to rapidly the above highlands of 2500 meters of height above sea level; conventionally can there is acute high altitude reaction; this is mainly because oxygen is under-supply in altitude environment; due to due to the low pressure of highlands, acute hypoxia injury that low-oxygen environment causes; and can cause the change of the aspects such as function of human body, metabolism, can threat to life when serious.For Altitude, most people can adapt to gradually by self-regulation, only have sub-fraction people can produce a series of symptom.Conventionally adopt at present the method for Altitude pre-adaptation to improve people's adaptive capacity, but this method is subject to a lot of condition restriction, for example, need the main equipments such as Altitude acclimatization cabin, causes it to promote the use of and acquires a certain degree of difficulty.Therefore, to environment of low oxygen plateau, by preventive medicine, promote Hypoxia Preconditioning to prevent still to seem extremely important.
Meanwhile, a lot of mining is at present produced in order to reduce the generation of gas explosion, previous ventilation is reduced to the method for gas density, is replaced by the method that reduces oxygen concentration, to avoid the danger of gas explosion.Under normal barometric pressure and temperature conditions, oxygen content 12% or be the place of safety of gas explosion below, but can cause like this oxygen supply deficiency, bring inconvenience to underground work personnel, and then can make these personnel that hypoxia reaction occurs.Meanwhile, recent frequent mine landslide, also can make underground work personnel in temporary transient low-oxygen environment.Although these personnel can carry oxygen cylinder work, also reduced labor intensity simultaneously.Therefore, the medicine of the down-hole low-oxygen environment pre-adaptation making new advances if can develop, improves body constitution to underground work personnel, avoids unexpected and occurs and increase work efficiency all significant.This type of situation is also often seen in the events such as earthquake disaster, and the narrow and small environment in the part personnel wherein that are easy to cause that cause due to landslide etc. produce hypoxia injury reaction.
In clinical practice, hypoxia-ischemia is a kind of serious disease, and blood vessel infraction will cause hypoxia when causing ischemia, therefore when Ischemia Time exceedes a specified time, pathologic will occur vascular endothelial cell changes, and causes the generation of apoplexy and the deterioration of patient health situation.Due to the caused damage serious harm of hypoxia-ischemia health, and prophylactic agent is very few at present, therefore seeks to be used for preventing the medicine of infraction that hypoxia-ischemia causes to seem extremely urgent.Meanwhile, while carrying out surgical operation clinically, doctor often can improve patient's prognosis by the aortal mode of artificial compressing patient and recover, but the effect of this mode can lack unified standard because of the difference of doctor's maneuver.If can give patient and promote the medicine of hypoxia-ischemia pre-adaptation, obviously more be conducive to operating therapeutic effect clinically.
In sum, the exploitation medicine that effectively antagonism hypoxia (Altitude, mine hypoxia, landslide hypoxia), hypoxia-ischemia damage has become a urgent problem.
Sodium sulfite is used as chemical reagent for a long time always, and uses as food additive, but not for pharmaceutical field.Applicant previously pointed out to utilize sodium sulfite can be used for setting up hypoxia and anoxia model in patent of invention 201010119570.4 (utilizing sodium sulfite to set up method and a kind of hypoxia and the anoxia model of hypoxia and anoxia model), the data of sodium sulfite hypoxia model have been obtained, for important foundation has been established in the medicinal application of sodium sulfite.But, medicament research and development, chemical reagent shift need to have corresponding standard for medicinal application, wherein there are a lot of difficulties to overcome, thus, applicant intends the medicinal usage to sodium sulfite and application mode research on the basis of sodium sulfite hypoxia model, and is expected to achievement in research to be converted into effective medicine and/or health product.
Summary of the invention
The invention provides sodium sulfite (Na
2sO
3) the new purposes of one, be the application of sodium sulfite in the functional components of preparation prevention hypoxia injury and/or hypoxia-ischemia relevant disease, this functional components can be used for the medicine of preparation prevention hypoxia injury and/or hypoxia-ischemia relevant disease, or alleviates in related indication health product, functional beverage or functional food.
Described sodium sulfite (Na
2sO
3) be pharmaceutical grade Na
2sO
3.
Described hypoxia injury and/or hypoxia-ischemia relevant disease or related symptoms can result from the low-oxygen environments such as Altitude area, sports, mine or other improper ventilation working space, specifically can be disease or the symptoms such as plateau pneumochysis, high altitude cerebral adema, cerebral ischemia, heart ischemia, respiratory distress.
New purposes of the present invention relates to the prophylactic agent of described relevant disease.The active component of described medicine is sodium sulfite (Na
2sO
3).Described medicine is the sodium sulfite (Na of concentration 0.1-1% (mass percent)
2sO
3) aqueous solution.Described medicine can adopt the dosage forms such as oral liquid or intravenous injection.When needing, in said medicine, can also add one or more pharmaceutically acceptable adjuvants, described adjuvant can comprise absorption enhancer, surfactant, lubricant, stabilizing agent, diluent, binding agent and the wetting agent etc. of field of pharmacology routine, also can add if desired pigment, sweeting agent and flavouring agent etc.The consumption of said medicine is generally pressed Na
2sO
3amount is counted 50-250ml/ people, and every day, 1-2 dosage, was generally 3-5 days the course for the treatment of.Dosage and the course for the treatment of all can be according to practical situation adjustment.
The present invention also provides a kind of alleviation hypoxia related indication health product.Described health product at least comprise: Na
2sO
30.05-2% (percentage by weight), vitamin C (Vc) 1-3%, tea polyphenols 1-15% and resveratrol 2-20%.Described health product are oral liquid, buccal tablet, chewable tablet, effervescent tablet, tablet, capsule, granule or soft capsule, can also add the acceptable adjuvant of various preparations in above-mentioned health care.
The present invention also provides a kind of alleviation hypoxia related indication drink with function.Sodium sulfite (the Na of described drink with function for containing concentration 0.1-1% (mass percent)
2sO
3) drinking water.When needing, can also add acceptable adjuvant in one or more beverage fields in above-mentioned functions beverage, described adjuvant comprises vitamin C and tea polyphenols etc.
The present invention also provides a kind of alleviation hypoxia related indication functional food.The function ingredients of described functional food is sodium sulfite (Na
2sO
3).Described Na
2sO
3the constituent of functional food comprises: Na
2sO
30.1-10% (percentage by weight), Vc 1-5%, dietary fiber 9-28.5% and starch 70-85%.Described functional food specifically can be and contains 1-100g/kg sodium sulfite (Na
2sO
3) cookies or bread.
The above-mentioned product relevant to sodium sulfite all can be according to the conventional method preparation separately of medicine, health product, beverage and food.
Na of the present invention
2sO
3the usage of product includes but not limited to:
Use sodium sulfite drinking-water, intravenous injection sodium sulfite injection, edible sodium sulfite health product or functional food, not only can be used for intending plateau crowd, also can be used for improving individual and athletic healthy physical ability, reach the object that promotes physical ability in altitutde training.
Above-mentioned usage is also applicable to operating personnel or the animal in the bad spaces of local ventilation such as mine and uses, and can extend the time window of personnel or animal tolerance hypoxia.
Further, while performing the operation for patients such as cerebral ischemia, heart ischemias clinically, tend to use the modes such as aorta of oppressing in the preoperative, reduce the perfusion flow of blood to target organ, thereby give the signal of an ischemic preconditioning of corresponding organ.Similarly, therefore sodium sulfite solution also can be used as adjuvant drug or the health product before cardiovascular and cerebrovascular disease operative treatment clinically, can make body in advance can perception hypoxia, the signal such as anoxia, ischemia, thereby the success rate that is conducive to improve operation, for example, alleviate or reduce extent of hemorrhage etc.
The invention provides sodium sulfite (Na
2sO
3) the new purposes of one, at the medicine of preparation prevention hypoxia injury and/or hypoxia-ischemia relevant disease with prevent the application in health product that hypoxia injury is relevant.Results of animal shows: (1) lumbar injection sodium sulfite is after 4 hours, mice is placed in to acute altitude hypoxia environment, observe its survival rate, the certain density sodium sulfite of lumbar injection can be found to pass through in advance, the survival rate of mice under acute altitude hypoxia condition can be significantly improved; (2) lumbar injection sodium sulfite, after 4 hours, is placed in acute normal pressure low oxygen environment by mice, observes its mortality rate, can find the certain density sodium sulfite of lumbar injection in advance, can significantly reduce the mortality rate of mice under acute normal pressure low oxygen condition; (3) to middle cerebral artery infarction (MCAO) model mice, when sodium sulfite respectively with 6.25,12.5, the concentration abdominal cavity of 25mg/Kg gives after animal, the cerebral infarct size of mice has reduced respectively 17%, 23%, 33%, explanation is along with the increase of concentration of sodium sulfite, and animal is enhanced for the ability of hypoxia-ischemia pre-adaptation.Above-mentioned experimental result shows that lumbar injection sodium sulfite can resist acute altitude hypoxia damage, the damage of acute normal pressure low oxygen, plays a protective role to the mice under hypoxia-ischemia condition.Therefore, can become using sodium sulfite as active fraction preparation the medicine of prevention hypoxia injury and/or hypoxia-ischemia relevant disease, prevention hypoxia injury and/or relevant health product, functional food or the drink with function of hypoxia-ischemia, can make body in advance in hypoxia (as Altitude, mine hypoxia etc.) pre-adaptation state, thereby reach the object of prevention hypoxia injury and/or hypoxia-ischemia relevant disease (as plateau pneumochysis, high altitude cerebral adema, cerebral ischemia, heart ischemia, respiratory distress etc.).Medicine of the present invention has the following advantages: 1) curative effect is obvious; 2) without toxicity, side effect, safe; 3) sodium sulfite is cheap; 4) medication convenient (be easy to carry, take).For hypoxia reaction and hypoxia-ischemia, damage caused fatigue, circulatory function obstacle, respiratory function declines, immunologic hypofunction, the symptom effect of being short of physical strength etc. is remarkable, medicine of the present invention and health product can be used for preventing hypoxia (especially altitude sickness) and hypoxia-ischemia, alleviation hypoxia/hypoxia-ischemia reacts the various symptoms medicine of the present invention causing and accelerates to adapt to especially environment of low oxygen plateau of hypoxia for normal oxygen environment acclimatization person, the military operation ability of the health level of raising personnel or animal and army personnel, the fight capability that strengthens army has major application and is worth, also can significantly promote to need the personnel by low-oxygen environment especially Altitude training raising physical ability in the past, make it accelerate to adapt to low-oxygen environment and improve physical ability achievement.Meanwhile, medicine of the present invention (or food or health product) is for the symptom that alleviates hypoxia-ischemia relevant disease patient, and the health level that improves the hypoxia-ischemia Diseases such as apoplexy is significant, has a extensive future.
Below in conjunction with specific embodiment, the present invention is described in further details.
The specific embodiment
Embodiment implements under take technical solution of the present invention as prerequisite, provided detailed embodiment and concrete operating process, but protection scope of the present invention is not limited to following embodiment.
In following embodiment, method therefor is conventional method if no special instructions.
Embodiment 1, sodium sulfite (Na
2sO
3) protective effect to Altitude damage mice
Laboratory animal: clean level C57BL/6J mice, male, in 6-7 week, body weight 18 ± 2g, is provided by Military Medical Science Institute's Experimental Animal Center.Isolated rearing 24h, the special feed of feeding, drinking public water supply, allows free diet.This experiment is by mice random packet.
Sodium sulfite (Na
2sO
3): pharmaceutical grade.0.9% physiological saline solution, now with the current.
Medication: Na
2sO
3administration group according to 6.25,12.5,25mg/Kg body weight is divided into three variable concentrations and gives lumbar injection, for three days on end, inject once every day, after last injection, 4h starts to carry out acute altitude hypoxia experiment, contrasts as blank group and normal saline matched group.
Acute hypoxia injury processing: mice is placed in to the transparent animal experimental chamber of hypobaric hypoxia, with air in pump extraction cabin, in cabin, altitude simulating is increased to 10000m with uniform speed 6min, maintain this height, and start writing time, until animal ceases breathing, as animal after 20min still has breathing, be judged to be survival.In experiment, record two indexs, i.e. time-to-live and survival rate.Time-to-live: the death time (be accurate to second) of animal in 20min.Survival mice is calculated the time-to-live according to 20min.Survival rate: the sum of the amount of survival/animal of animal after 20min.
Date processing: according to mean survival time and survival rate, carry out statistical analysis with statistic software SPSS ver 15.0.Through the difference of t-check more each treated animal time-to-live and survival rate.
Result is as shown in table 1, and when mice is elevated to rapidly to height above sea level 10000m (partial pressure of oxygen is as 4.7kPa) within 6min take uniform speed, control group mice plurality in 20min is dead.The oxygen environment of this phenomenon explanation 10000m height above sea level is fatal low-oxygen environment for mice.Different from matched group, mice is used respectively after sodium sulfite lumbar injection 4h, then carries out the acute hypoxia experiment of height above sea level 10000m, and in 20min, mouse death rate obviously reduces, significant difference compared with matched group (P < 0.05).Above results suggest, gives sodium sulfite and can significantly improve the survival rate of animal under acute hypoxia condition before acute hypoxia.
The protective effect of table 1 sodium sulfite to acute altitude hypoxia damage
| Group | Sample size (n) | Time-to-live (min) | Survival rate (%) |
| Blank | 25 | 12.59±7.02 | 35.00±10.00 |
| Normal saline contrast | 15 | 13.27±6.51 | 40.00±0.00 |
| 6.25mg/Kg | 20 | 14.65±6.50 | 46.67±11.55 |
| 12.5mg/Kg | 15 | 16.89±5.22 # | 63.33±15.28 # |
| 25mg/Kg | 15 | 17.44±4.41 # | 73.33±23.09 # |
This experimental verification the preventive effect of sodium sulfite to Altitude damage.
Embodiment 2, sodium sulfite (Na
2sO
3) protective effect to hypoxia under normal pressure (mine operation) damage mice
Laboratory animal: clean level C57BL/6J mice, male, in 6-7 week, body weight 18 ± 2g, is provided by Military Medical Science Institute's Experimental Animal Center.Isolated rearing 24h, the special feed of feeding, drinking public water supply, allows free diet.This experiment is by mice random packet.
Sodium sulfite (Na
2sO
3): pharmaceutical grade.0.9% physiological saline solution, now with the current.
Medication: Na
2sO
3administration group according to 6.25,12.5,25mg/Kg body weight is divided into three variable concentrations and gives lumbar injection, Na
2sO
3lumbar injection for three days on end, inject once by every day, and after last injection, 4h starts to carry out acute normal pressure low oxygen experiment, contrasts as blank group and normal saline matched group.
Acute hypoxia injury processing: mice is placed in to the transparent animal experimental chamber of normal pressure low oxygen, extracts air in cabin out with pump, in cabin, oxygen content is 3.25%, maintain the oxygen of this concentration, and start writing time, until animal ceases breathing, as animal after 10min still has breathing, be judged to be survival.In experiment, record two indexs, i.e. time-to-live and mortality rate.Time-to-live: the death time (be accurate to second) of animal in 10min.Survival mice is calculated the time-to-live according to 10min or 15min.Mortality rate: the sum of the dead quantity/animal of animal after 10min.
Date processing: according to mean survival time and mortality rate, carry out statistical analysis with statistic software SPSS ver 16.0.Through the difference of t-check more each treated animal time-to-live and mortality rate.
Result is as shown in table 2, and by mice, when oxygen content is 3.25%, control group mice is all dead in 10min.The oxygen environment that this phenomenon explanation oxygen content is 3.25% is fatal low-oxygen environment for mice.Different from matched group, mice is with after sodium sulfite lumbar injection 4h, carry out again oxygen content and be 3.25% acute hypoxia experiment, in 10min, mice exceedes half survival, and still old survival phenomenon of mice in 15min, significant difference compared with matched group (P < 0.05).Above results suggest, the front 4h of acute hypoxia gives sodium sulfite and can significantly reduce the mortality rate of animal under acute normal pressure low oxygen condition.
The protective effect of table 2 sodium sulfite to acute normal pressure low oxygen damage
| Group | Sample size (n) | Time-to-live (min) | Mortality rate (%) |
| Blank | 22 | 4.14±2.62 | 100.00±0.00 |
| Normal saline contrast | 20 | 4.93±3.11 | 100.00±0.00 |
| 6.25mg/Kg | 20 | 4.48±3.73 | 75.00±37.86 |
| 12.5mg/Kg | 20 | 6.10±3.30 # | 70.00±11.55 # |
| 25mg/Kg | 20 | 7.26±3.20 # | 55.00±25.17 # |
This experimental verification the preventive effect of sodium sulfite to hypoxia injury in the situations such as mine, respiratory distress syndrome (ivrds).
Embodiment 3: sodium sulfite (Na
2sO
3) protective effect to hypoxia-ischemia damage mice
Laboratory animal: clean level C57BL/6J mice, male, in 6-7 week, body weight 18 ± 2g, is provided by Military Medical Science Institute's Experimental Animal Center.Isolated rearing 24h, the special feed of feeding, drinking public water supply, allows free diet.
This experiment is by mice random packet.
Sodium sulfite (Na
2sO
3): pharmaceutical grade.0.9% physiological saline solution, now with the current.
Medication: Na
2sO
3administration group according to 6.25,12.5,25mg/Kg body weight is divided into three variable concentrations and gives lumbar injection, for three days on end, inject once every day, after last injection, 4h starts to carry out hypoxia-ischemia injury experiment.Adopt line bolt legal system for middle cerebral artery infarction (MCAO) model, simulate common clinically apoplexy damage, with brain infarction area, the effect of dry sodium sulfite intervention protection is judged.Contrast is blank group and normal saline matched group.
Middle cerebral artery infarction (MCAO) model preparation: lumbar injection Na
2sO
3after 1～4 hour, preparation mouse brain medium-sized artery cerebral infarction models.Operation group mice after chloral hydrate anesthesia, ligation bilateral common carotid arteries 30min, then get cerebral tissue after perfusion 20min.The cerebral tissue taking out carries out TTC dyeing, measures infarct size, the relatively variation of animal brain infarct size before and after sodium sulfite intervention protection.
Date processing: with animal brain's infarct size, carry out statistical analysis with SPSS ver 16.0 softwares.By the infarct size difference of the more each treated animal of Fisher Precision Test method, by the more each treated animal infarct size of the t-method of inspection difference of independent sample.
Experimental result: with respect to the negative control group of normal saline, abdominal cavity gives after variable concentrations sodium sulfite, and the cerebral infarct size of mice is able to remarkable minimizing.Particularly; when sodium sulfite respectively with 6.25,12.5, the concentration abdominal cavity of 25mg/Kg gives after animal; the cerebral infarct size of mice has reduced respectively by 17%, 23%, 33% (all P < 0.05); explanation is along with the increase of concentration of sodium sulfite; animal is enhanced for the ability of hypoxia-ischemia pre-adaptation; thereby follow-up while carrying out cerebrum ischemia hypoxia injury; can reduce the protective effect for visceral organ injury after operation, and there is certain dose-effect relationship.
This experimental verification sodium sulfite give in advance the preventive protection effect to animal hypoxia-ischemia damage.This sentences cerebral ischemia hypoxia injury is that example is verified the intervention protection of sodium sulfite; its result also extends to the pre-adaptation protective effect in the hypoxia-ischemia operations such as such as heart, kidney, liver of other organs clinically, and sodium sulfite gives effectively to reduce the damage of internal organs after operation process and operation clinically in advance.
Embodiment 4: sodium sulfite (Na
2sO
3) toxicity test
Sodium sulfite is common food preservative, antistaling agent and depigmenting agent, and it is widely used in food-processing industry.Sodium sulfite has had the history of a lot of years at food-processing industry as antiseptic.Studies have found that sodium sulfite (Na
2sO
3) median lethal dose(LD 50) (LD in mice
50) be 5989mg/Kg body weight (Okahara. (1963) .FoodHygiene Journal (Shokuhin Eiseigaku Zassi) 4:15).The researchs such as Nair are pointed out, Na
2sO
3in cosmetics use, be safe (Nair B, Elmore AR.Final report on the safety assessment of sodiumsulfite, potassium sulfite, ammonium sulfite, sodium bisulfite, ammonium bisulfite, sodiummetabisulfite and potassium metabisulfite.Int J Toxicol.2003; 22Suppl 2:63-88).In addition, research is found, Na
2sO
3in the mankind, can use the amount (Gilman of 300mg/Kg body weight, A.G., Goodman, L.S., Gilman, A. (eds). (1980) .Goodman and Gilman ' s the Pharmalogical Basis of Therapeutics.6th ed.New York:Macmillan Publishing Co.Inc.p.1005.).These all illustrate, Na
2sO
3toxicity very little, can in medicine, use safely.
Embodiment 5, Na
2sO
3the preparation of injection
Constituent: Na
2sO
3injection, the Na that is 0.1-1% by percentage by weight
2sO
3, sodium chloride and water for injection composition.
Na
2sO
3the preparation method of injection: by pharmaceutical grade Na
2sO
3(being purchased) dissolves with water for injection, then add sodium chloride, stir, finally add w/v 0.3% through the active carbon stirring and adsorbing of dry heat treatment (dry heat treatment method is 80 degree stove-dryings) 15 minutes, be filtered to clarity qualified rear for embedding; Described filtration comprises that the coarse filtration decarburization of titanium rod filter (reaching filter plant factory purchased from Shijiazhuang hundred million), 0.45 μ m cartridge filter (purchased from the purifying equipment of upper voyage company limited) filter and 0.22 μ m cartridge filter (purchased from the purifying equipment of upper voyage company limited) fine straining triple filter.
This injection is suitable for intravenous injection.For the prevention of the diseases such as Altitude, hypoxia-ischemia, previously used, the each 50-250ml/ people of using dosage, every day 1-2 time, using is continuously for 3-5 time a course for the treatment of.Use intravenous injection sodium sulfite injection, not only can be used for intending plateau crowd, also can be used for improving individual and athletic healthy physical ability, reach the object that promotes physical ability in altitutde training.Above-mentioned usage is also applicable to operating personnel or the animal in the bad spaces of local ventilation such as mine and uses, and can extend the time window of personnel or animal tolerance hypoxia.
Further, while performing the operation for patients such as cerebral ischemia, heart ischemias clinically, tend to use the modes such as aorta of oppressing in the preoperative, reduce the perfusion flow of blood to target organ, thereby give the signal of an ischemic preconditioning of corresponding organ.Similarly, sodium sulfite solution also can be used as adjuvant drug or the health product before cardiovascular and cerebrovascular disease operative treatment clinically, can make the body in advance can perception hypoxia and the signal such as anoxia, thereby be conducive to improve the success rate of operation, for example, alleviate or reduce extent of hemorrhage etc.
Embodiment 6, Na
2sO
3the preparation of health product
Na
2sO
3the functional component of health product comprises (percentage by weight that accounts for health product total amount): Na
2sO
30.05-2%, Vc 1-3%, tea polyphenols 1-15%, resveratrol 2-20%.
Na
2sO
3the preparation method of health product: by Na
2sO
3, Vc, tea polyphenols and resveratrol mix homogeneously, obtain Powdered functional component, then according to conventional formulation method, make the Na of various dosage forms
2sO
3health product, the dosage form being suitable for can be oral liquid, buccal tablet, chewable tablet, effervescent tablet, tablet, capsule, granule or soft capsule.
These health product are suitable for occurring in prevention the use of the situations such as Altitude, hypoxia-ischemia, have previously taken, and take Na
2sO
3dosage is each 10-5000mg/ people, and every day 1-2 time, using is continuously for 3-5 time a course for the treatment of.Edible sodium sulfite health product, not only can be used for intending plateau crowd, also can be used for improving individual and athletic healthy physical ability, reach the object that promotes physical ability in altitutde training.Above-mentioned usage is also applicable to operating personnel or the animal in the bad spaces of local ventilation such as mine and uses, and can extend the time window of personnel or animal tolerance hypoxia.
Embodiment 7, Na
2sO
3the preparation of drink with function
Na
2sO
3the functional component of drink with function comprises (percentage by weight that accounts for beverage total amount): Na
2sO
30.1-1%, vitamin C (Vc) 1-3% and tea polyphenols 1-15%, use deionized water dissolving.
Na
2sO
3the preparation method of drink with function: by pharmaceutical grade Na
2sO
3with deionized water dissolving, then add Vc and tea polyphenols, stir, finally add w/v 0.3% through the active carbon stirring and adsorbing of dry heat treatment 15 minutes, be filtered to the qualified rear embedding of clarity; Described filtration comprises that the decarburization of titanium rod filter coarse filtration, 0.45 μ m cartridge filter filter and 0.22 μ m cartridge filter fine straining triple filter, obtain the liquid that contains functional component.Make routinely again beverage technique this liquid is added in drinking water or in other beverage, obtain Na
2sO
3drink with function.
This Na
2sO
3drink with function is applicable to drink to the personnel on Plain or animal, previously quotes, and can make personnel or animal reach the effect of Hypoxia Preconditioning, is equivalent to enter highlands.Drank the personnel of sodium sulfite drink with function or the adaptation that it's a few hours is past animal via, and can enter Altitude area, and can not produce the altitude sicknesses such as serious hypoxia or anoxia.
Embodiment 8, Na
2sO
3the preparation of functional food
Na
2sO
3the functional component of functional food comprises (percentage by weight that accounts for food total amount): Na
2sO
30.1-10%, vitamin C (Vc) 1-5%;
Na
2sO
3the preparation method of functional food: by Na
2sO
3add (dietary fiber 9-28.5wt% and starch 70-85wt%) in dietary fiber and starch with Vc functional component, then processing technology is made cookies or bread routinely.
This Na
2sO
3functional food is applicable to previously edible, not only can be used for intending plateau crowd, also can be used for improving individual and athletic healthy physical ability, reaches the object that promotes physical ability in altitutde training.
Above-mentioned usage is also applicable to operating personnel or the animal in the bad spaces of local ventilation such as mine and uses, and can extend the time window of personnel or animal tolerance hypoxia.
Claims (9)
1. the application of sodium sulfite in the functional components of preparation prevention hypoxia injury and/or hypoxia-ischemia relevant disease, it is characterized in that, for the preparation of one, alleviate the related indication health product of hypoxia, its functional component is sodium sulfite, comprises by weight percentage Na in health product
2sO
30.05-2%, vitamin C 1-3%, tea polyphenols 1-15% and resveratrol 2-20%; Described hypoxia injury and/or hypoxia-ischemia relevant disease are plateau pneumochysis, high altitude cerebral adema, cerebral ischemia, heart ischemia or respiratory distress.
2. application according to claim 1, is characterized in that: described sodium sulfite is pharmaceutical grade Na
2sO
3.
3. application according to claim 1, is characterized in that: described hypoxia injury and/or hypoxia-ischemia relevant disease are to result from the disease that Altitude area, exercise factor, mine or other improper ventilation working space low-oxygen environment cause.
4. alleviate the related indication health product of hypoxia, its functional component is sodium sulfite, comprises by weight percentage Na in health product
2sO
30.05-2%, vitamin C 1-3%, tea polyphenols 1-15% and resveratrol 2-20%.
5. health product according to claim 4, is characterized in that: be oral liquid, tablet, capsule or granule.
6. health product according to claim 5, is characterized in that: described tablet is buccal tablet, chewable tablet or effervescent tablet.
7. health product according to claim 5, is characterized in that: described capsule is soft capsule.
8. the application of sodium sulfite in the functional components of preparation prevention hypoxia injury and/or hypoxia-ischemia relevant disease, it is characterized in that, for the preparation of one, alleviate the related indication functional food of hypoxia, its function ingredients is sodium sulfite, comprises by weight percentage: Na in described functional food
2sO
30.1-10%, vitamin C 1-5%, dietary fiber 9-28.5% and starch 70-85%; Described hypoxia injury and/or hypoxia-ischemia relevant disease are plateau pneumochysis, high altitude cerebral adema, cerebral ischemia, heart ischemia or respiratory distress.
9. alleviate the related indication functional food of hypoxia, its function ingredients is sodium sulfite, in functional food, comprises by weight percentage: Na
2sO
30.1-10%, vitamin C 1-5%, dietary fiber 9-28.5% and starch 70-85%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110349992.5A CN102462695B (en) | 2010-11-08 | 2011-11-08 | Application of sodium sulfite |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010534892.5 | 2010-11-08 | ||
| CN201010534892 | 2010-11-08 | ||
| CN201110349992.5A CN102462695B (en) | 2010-11-08 | 2011-11-08 | Application of sodium sulfite |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410040171.7A Division CN103751208B (en) | 2010-11-08 | 2011-11-08 | The new purposes of sodium sulfite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102462695A CN102462695A (en) | 2012-05-23 |
| CN102462695B true CN102462695B (en) | 2014-05-07 |
Family
ID=46067003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110349992.5A Expired - Fee Related CN102462695B (en) | 2010-11-08 | 2011-11-08 | Application of sodium sulfite |
| CN201410040171.7A Expired - Fee Related CN103751208B (en) | 2010-11-08 | 2011-11-08 | The new purposes of sodium sulfite |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410040171.7A Expired - Fee Related CN103751208B (en) | 2010-11-08 | 2011-11-08 | The new purposes of sodium sulfite |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN102462695B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450048A (en) * | 2007-11-30 | 2009-06-10 | 中国人民解放军军事医学科学院基础医学研究所 | Acute hypoxia injury resistance use of teprenone |
-
2011
- 2011-11-08 CN CN201110349992.5A patent/CN102462695B/en not_active Expired - Fee Related
- 2011-11-08 CN CN201410040171.7A patent/CN103751208B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450048A (en) * | 2007-11-30 | 2009-06-10 | 中国人民解放军军事医学科学院基础医学研究所 | Acute hypoxia injury resistance use of teprenone |
Non-Patent Citations (4)
| Title |
|---|
| 二氧化硫对低氧性肺动脉高压大鼠肺动脉结构的影响;田悦等;《中华儿科杂志》;20080930;第46卷(第9期);675-679页 * |
| 外源性二氧化硫对低氧性肺动脉高压大鼠肺动脉压力的影响;田悦等;《实用儿科临床杂志》;20071130;第22卷(第22期);1729-1730、1736页 * |
| 田悦等.二氧化硫对低氧性肺动脉高压大鼠肺动脉结构的影响.《中华儿科杂志》.2008,第46卷(第9期),675-679页. |
| 田悦等.外源性二氧化硫对低氧性肺动脉高压大鼠肺动脉压力的影响.《实用儿科临床杂志》.2007,第22卷(第22期),1729-1730、1736页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102462695A (en) | 2012-05-23 |
| CN103751208A (en) | 2014-04-30 |
| CN103751208B (en) | 2016-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8778410B2 (en) | Oral or enteral composition useful for recovery of physical functions | |
| KR20220137663A (en) | Chinese medicine complex prescription with detoxification function and its use | |
| CN103735838B (en) | One breeding kidney health care medicinal liquor for tonifying kidney and preparation method thereof | |
| KR101870846B1 (en) | Multi-functional composition and preparation method and application thereof | |
| CA2332038C (en) | Novel pharmaceutical composition for use in emergency treatment and preparation method thereof | |
| CN103054044A (en) | Sleep-improving health food composition | |
| CN104224885A (en) | Traditional Chinese medicine composition for relieving physical fatigue | |
| Turner et al. | A fatal ingestion of caffeine | |
| CN106236927A (en) | A kind of Chinese medicine composition with enhancing immunity and antifatigue effect and preparation method thereof and purposes | |
| CN104688784A (en) | Use of bilobalide in preparation of hypotensor | |
| CN102462695B (en) | Application of sodium sulfite | |
| CN103202506B (en) | One produces refreshing effect to the mind plant beverage and production method thereof | |
| JPH07196523A (en) | Solution for internal use containing quercetin glycoside | |
| Bassett et al. | The Mineral Exchanges of Man: II. Effect of Excess Potassium and of Calcium on Two Normal Men and on an Oedematous Nephritic | |
| CN104223073A (en) | Food, health-care product or pharmaceutical composition for sleep aiding | |
| CN109453317A (en) | A kind of anaesthetic and its preparation process for strengthening by means of tonics | |
| Shrestha et al. | Mad honey poisoning: a rare case report of seven cases | |
| US20050153020A1 (en) | Composition comprising phosphate | |
| CN104147053A (en) | Oral liquid of traditional Uygur medicine named Kulumuti, and preparation method thereof | |
| CN101152196A (en) | Application of notoginsen triterpenes and its monomer in preparing medicament for treating melancholia | |
| CN107308317A (en) | A kind of construction method for the Chinese medicine composition and radiation injury animal model for preventing and treating radiation injury | |
| CN104106826B (en) | A kind of gadol beverage and preparation method thereof | |
| CN106729518A (en) | A kind of tea beverage of hypotensive and preparation method and application | |
| CN108433106A (en) | A kind of Oxygen-deficient endurance fructose powder (liquid) composition | |
| CN103830217B (en) | Sodium Pyruvate application in hyperchloremic acidosis medicine is alleviated in preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140507 Termination date: 20171108 |